June 28, 2021
2 min watch
Save
VIDEO: New IDH inhibitor ‘pretty impressive’ in high-risk AML
In this video, Aaron T. Gerds, MD, from the Cleveland Clinic Taussig Cancer Institute, discusses a new IDH inhibitor, olutasidenib, which was found to be well tolerated in patients with relapsed or refractory acute myeloid leukemia.
The phase 2 clinical trial, presented at ASCO21, evaluated 153 patients, and produced complete remission in a population of patients with refractory or relapsed high-risk AML with mutations in IDH1.
“The efficacy was pretty impressive,” Gerds said. “This drug had a pretty remarkable safety profile, so it might potentially be a better partner for other chemotherapies and targeted therapies in the future.”
Published by:
Sources/Disclosures
Collapse
Source:
De Botton, S, et al. Abstract 7006. Presented at: ASCO Annual Meeting (virtual meeting); 2021; June 4-8, 2021.
Disclosures:
Gerds reports no relevant financial disclosures.
Read more about